Available online on 15.05.2020 at <http://ujpr.org>
Universal Journal of Pharmaceutical Research
An International Peer Reviewed Journal

Open access to Pharmaceutical research
 This is an open access article distributed under the terms of the Creative Commons Attribution-Non
 Commercial Share Alike 4.0 License which permits unrestricted non commercial use,
 provided the original work is properly cited

Volume 5, Issue 2, 2020

Open Access

REVIEW ARTICLE

QUALITY EVALUATION OF BIOSIMILAR MEDICINES: AN OVERVIEW

Emrah KORKMAZ¹, Mehmet Emre ÖZDEMİRHAN², Evren ALGIN YAPAR^{3*}

Department of Analysis and Control Laboratories, Turkish Medicines and Medical Devices Agency, 06430 Çankaya, Ankara, Turkey.

ABSTRACT

Biosimilar medicines are biotherapeutics that are similar in quality, safety and efficacy to previously licensed reference biotherapeutics. The slightest change in any stage of production can cause differences in the product. Among the factors, affecting production can be listed as; host cell selection, fermenter type, ambient conditions, broth, substances used for cell culture, fermentation method and purification method. The similarity should be demonstrated by comparative quality, non-clinical and clinical tests. Research and development studies in the biopharmaceutical field bring diversity of quality control methods along with the formulation and manufacturing method of the biosimilars. Although there are some standardized and validated quality control methods given in the internationally recognized pharmacopoeias, there are many in house methods of biopharmaceutical product owners that can only be used as internal quality control methods by them. The main international sources for quality control methods of biopharmaceutics can be given as pharmacopoeias, International Organization for Standardization standards and Organization for Economic Co-operation and Development methods. In this review manufacturing process, regulatory guidelines and quality control of biosimilar medicines briefly are given.

Keywords: Biosimilars, biotherapeutics, manufacturing, quality control, pharmacopoeial methods.

Article Info: Received 5 March 2020; Revised 6 April; Accepted 3 May, Available online 15 May 2020

Cite this article-

KORKMAZ E, ÖZDEMİRHAN ME, ALGIN YAPAR E. Quality evaluation of biosimilar medicines: an overview. Universal Journal of Pharmaceutical Research 2020; 5(2):54-57.

DOI: <https://doi.org/10.22270/ujpr.v5i2.390>

Address for Correspondence:

Assoc. Prof. Evren ALGIN YAPAR, Department of Analysis and Control Laboratories, Turkish Medicines and Medical Devices Agency, 06430 Çankaya, Ankara, Turkey. Tel: +903125655370, E-mail: evrenalgin@yahoo.com

INTRODUCTION

Biosimilar medicines are biotherapeutics that are similar in quality, safety and efficacy to previously licensed reference biotherapeutics¹. Since the exact production method of the reference biological product is not known, different processes are mostly used in the production of biosimilar drugs. The slightest change in any stage of production can cause differences in the product. Among the factors, affecting production can be listed as; host cell selection, fermenter type, ambient conditions, broth, substances used for cell culture, fermentation method and purification method². Good Manufacturing Practices-GMP requirements for biological and biosimilar products are higher than for small molecules. The similarity should be demonstrated by comparative quality, non-clinical and clinical tests^{1,3}. While non-clinical tests can be grouped as physicochemical characterization, biological characterization, pre-clinical and pharmacokinetic-PK/pharmacodynamic-PD tests, clinical tests can be grouped as PK-PD tests, all reliability and effectiveness studies and clinical studies. Biosimilar products have high degree of similarity to the reference products⁴. Research and development studies in the

biopharmaceutical field bring diversity of quality control methods along with the formulation and manufacturing method of the biosimilars under the biological/biotechnological medicines. Although there are some standardized and validated quality control methods given in the internationally recognized pharmacopoeias, there are many in house methods of biopharmaceutical product owners that can only be used as internal quality control methods by them. The main international sources for quality control methods of biopharmaceutics can be given as pharmacopoeias⁵⁻⁹ International Organization for Standardization-ISO standards¹⁰ and Organization for Economic Co-operation and Development-OECD methods¹¹. Between the pharmacopoeias European Pharmacopoeia, United States Pharmacopoeia, British Pharmacopoeia and Japanese Pharmacopoeia are mostly accepted ones. In the scope of above mentioned pharmacopoeias the analyses of biological and biotechnological medicines can be grouped as physical, chemical, pharmacological and microbiological controls. Those include identity, quantity and potency tests, thermostability, viral control tests, total and bound protein and purity (impurity) controls, sterility test, bacterial endotoxin and pyrogenicity test to prove

their efficacy and safety. In this review, biosimilar medicines are briefly overviewed in the scope of regulations, manufacturing and quality control methods take place in the international standards such as pharmacopoeias.

Regulatory Guidelines for Biosimilars

Regulatory guidelines for biosimilars released by *European Medicines Agency-EMA*¹, *U.S. Food And Drug Administration-FDA*¹¹ and *World Health Organisation-WHO*¹² are listed below.

European Medicines Agency

- ✓ Guidelines on Similar Biological Medicinal Products
- ✓ Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance: Non-Clinical and Clinical Issues
- ✓ Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substances: Quality Issues
- ✓ Questions and Answers on Biosimilar Medicines (Similar Biological Medicinal Products).

U.S. Food And Drug Administration

- ✓ Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product
- ✓ Guidance for Industry: Quality Considerations in Demonstrating Biosimilarity to a Reference Product
- ✓ Guidance for Industry: Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product.

World Health Organisation

- ✓ Guidelines for Evaluation of Similar Biotherapeutic Products-SBPs.

Manufacturing Process of Biosimilars

Basic steps for manufacturing process of biosimilars are presented in Figure 1 and the critical factors for these steps are given below².

Figure 1: Basic steps for manufacturing process of biosimilars.

Critical factors that are effective on the success of the manufacturing steps are given below.

Cell line selection

- Mammalian
- Bacteria
- Yeast

Cell culture process development

- Oxygen levels

- Lactate production
- Temperature
- pH
- Osmolality
- Duration

Purification process

- Column chromatography
- Filtration
- Centrifugation

Formulation

- Buffer conditions
- pH
- Ionic strength
- Excipients amounts
- The final formulation (liquid, frozen liquid or lyophilisate)

Quality Control of Biosimilars

Under the class of biological and biotechnological medicines the biosimilars are analysed for below given tests and surveillance in terms to prove their quality¹³.

Characterization

Characterization of biological and biotechnological medicines are evaluated according to the ICH Q6B guideline¹⁴.

○ Physicochemical Properties

- Composition determination
- Physical determination
- Primary Structure determination
- Heterogenity (activity, efficacy, safety)

○ Biological Activity

- Biological Assay (animal based, cell culture based, biochemical assay)
- Potency

○ Immunochemical properties

- Affinity
- Avidity
- Immunoreactivity

○ Puritiy, impurity, and contaminants

○ Quantity

Stability

The effect of temperature, humidity, accelerated and stress conditions, light, container/closure system, stability after reconstitution of freeze-dried product variables on stability is evaluated in terms of the following parameters, which are indicated in the ICH Q5C guideline¹⁵;

- Potency
- Purity and Molecular Characterisation
- Other Characteristics;
 - Visual appearance (colour and opacity for solutions/suspensions; colour, texture and dissolution time for powders).
 - Visible particulates (solutions or after the reconstitution of powders or lyophilised cakes)
 - pH,
 - Moisture level (powders and lyophilised products).
 - Sterility testing or alternatives (e.g., container/closure integrity testing)
 - Effect of additives (exipients, stabilisers, preservatives etc.) have to be evaluated.

Table 1: Pharmacopoeial methods for quality control of biopharmaceuticals.

	Spesification	Measurement
General Tests	pH	Calibrated pH meter
Identity and Heterogeneity	Dissolved molecule concentration	Osmolality
	Charge paternity	Ion-Exchange Chromatography
	Molecule weight	
	Primer structure	
	High level structure	Nuclear Magnetic Rezonanse-NMR, circular dichroism
	Glycolysation heterogeneity	Gas Chromatography/monosaccharide structure analysis with Mass Spectrometry, oligosaccharide analysis
	Amino terminal determination of protein	N terminal sequencing and HPLC
	Carboxy terminal determination of protein	C-terminal sequencing with a combination of peptide mapping and electrospray ionization-mass spectrometry/mass spectrometry
Purity and Impurities	Fragments and isoforms	SDS-PAGE (reduced and non-reduced) HPLC, ultra-HPLC, liquid chromatography/mass spectrometry
	Deamidation products	IEF, Ion exchange chromatography, peptide mapping
	Dimers and large aggregates	Size exclusion chromatography, ultracentrifuge, SDS PAGE
	Post-translational modifications	Peptide mapping, Liquid Chromatography-Electrospray Ionization/Mass Spectrometry
	Host Cell proteins	SDS PAGE, immunological tests
	Related proteins	SDS PAGE, immunological tests, HPLC, liquid chromatography/mass spectrometry
	Production-based impurities	Gas chromatography/mass spectrometry
Potens	Validated biological potency tests	Potens
Quantity	Protein content	UV scanning

Comparision Studies for Manufacturing Quality

Comparability of biotechnological/biological products subject to changes in their manufacturing process are presented in ICH Q5E Guideline interms of non-clinical and clinical studies¹⁶.

- Pharmacokinetic-PK
- Pharmacodynamic-PD
- PK/PD
- Clinical efficacy
- Specific safety
- Immunogenicity
- Pharmacovigilance

Since the quality control of biopharmaceutical products has a great prospect in terms of the safe access to treatment that patients need the quality of them must comply with relevant internationally accepted criteria. Quality in biopharmaceutical products is a broad concept covering all aspects that affect the efficacy and safety of these products. All of the measures that require the assurance of biopharmaceutical quality constitute the quality assurance system. The Quality Assurance system consists of Quality Management-QM, Quality Assurance-QA and Good Manufacturing Practices-GMP and Quality Control-QC. As quality control and analysis of biopharmaceutical products are a part of GMP, quality control analyses should be carried out using validated methods appropriately to ensure the quality of the product. Biopharmaceutical products are subjected to quality control criteria and analysis within the scope of internationally accepted standards and guidelines specified or guided, including formulation, place and form of use. The quality control

analyses made in biopharmaceutical products are mentioned below in the general framework within the scope of biopharmaceutical forms. Biological/biotechnological product analysis in pharmacopieas can be grouped as below and can be given in detail in Table 1⁵⁻⁸;

- Biological activity by cell culture method,
- Qualification and quantification by the Enzyme-Linked Immunosorbent Assay-ELISA and High Performance Liquid Chromatography-HPLC methods,
- Total and free polyribosylribitol phosphate-PRP quantification with Isoelectric Focusing-IEF, Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis-SDS PAGE, Western Blotting methods,
- *In vivo* Potency Test,
- *In vivo* Biological Reactivity Test,
- Physical tests: Physical controls, pH determination, total and bound protein, protein nitrogen, phenol, thimerosal, free formaldehyde, aluminium, humidity, residual humidity, phosphorus, PRP, sucrose, cresol, tween 80, glycine, ovalbumin, o-acetyl NaCl (salt) and volume,
- Sterility test (membrane filtration method),
- Limulus Amebocyte Lysate-LAL test,
- Pyrogen test.

It is critical to prove that biopharmaceutical products are continuously produced at the desired quality and meet the specified specifications to ensure effective and safe treatment. Therefore, all quality control analyses of the starting materials to the finished product are required as part of GMP. Which analyses are to be made for which biopharmaceutical product is

determined according to the guidelines of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use. With the developments in the pharmaceutical field, quality control tests will also diversify in parallel with newly developed innovative products and devices in addition to the mentioned analysis methods. For example; coulometric moisture determination with Karl Fischer method, particle size distribution and thermal analyses (Thermogravimetric Analysis-TGA, Differential Scanning Calorimetry-DSC) draws attention among the new tests that may be included in this variety.

CONCLUSION

Biosimilar products are gaining importance day by day, and there are many draft legislation and guidelines prepared by legal authorities for these products. In this direction, it will be useful to follow scientific and technological developments and current legislation during R&D, manufacturing and quality control stages.

AUTHOR'S CONTRIBUTION

All authors have worked equally for this work.

ACKNOWLEDGEMENTS

The authors extend their thanks and appreciation to the Turkish Medicines and Medical Devices Agency, Çankaya, Turkey to provide necessary facilities for this work.

CONFLICT OF INTEREST

No conflict of interest associated with this work.

REFERENCES

1. <https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines-overview> accessed on 10.03.2020.
2. Vulto AG, Jaquez OA. The process defines the product: what really matters in biosimilar design and production. *Rheumatology* 2017; 56: iv14-iv29. <https://doi.org/10.1093/rheumatology/kex278>
3. Agbogbo FK, Ecker DM, *et al.* Current perspectives on biosimilars. *J Ind Microbiol Biotech* 2019; 46(9-10): 1297-1311. <https://doi.org/10.1007/s10295-019-02216-z>
4. Dörner T, Isaacs J, Gonçalves J, Azevedo V, Castañeda-Hernández, G, Strohal R, McInnes I. Biosimilars already approved and in development. *Considerations in Medicine* 2017; 1(1): 7-12. <http://dx.doi.org/10.1136/conmed-2017-100004>
5. European Pharmacopoeia 10.0.
6. The United States Pharmacopoeia 42–National Formulary 37.
7. British Pharmacopoeia 2019.
8. Japanese Pharmacopoeia 17. Edition.
9. ISO Standards, <https://www.iso.org/standards.html> accessed on 10.03.2020.
10. OECD, <https://www.oecd.org/chemicalsafety> accessed on 10.03.2020.
11. FDA, <https://www.fda.gov> accessed on 10.03.2020.
12. WHO, <https://www.who.int/> accessed on 10.03.2020.
13. ICH, <https://www.ich.org/page/quality-guidelines> accessed on 10.03.2020.
14. ICH Q6B guideline, https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q-6-b-test-procedures-acceptance-criteria-biotechnological/biological-products-step-5_en.pdf accessed on 10.03.2020.
15. ICH Q5C guideline, https://www.ema.europa.eu/en/documents/scientific-guideline/ich-topic-q-5-c-quality-biotechnological-products-stability-testing-biotechnological/biological-products_en.pdf accessed on 10.03.2020.
16. ICH Q5E Guideline, https://database.ich.org/sites/default/files/Q5E_Guideline.pdf accessed on 10.03.2020.